Immunopharmacological and immunotoxicological activities of a water-soluble (1→3)-β-D-glucan, CSBG from Candida spp

International Journal of Immunopharmacology

Volumn 22, Issue 5, 2000, Pages 383-394

  Tokunaka, Kazuhiro ^a   Ohno, Naohito ^a   Adachi, Yoshiyuki ^a   Tanaka, Shigenori ^b   Tamura, Hiroshi ^b   Yadomae, Toshiro ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b SEIKAGAKU CORPORATION   (Japan)

Author keywords

glucan; Candida; Immunopharmacological activity; Macrophages

Indexed keywords

BETA GLUCAN; CYCLOPHOSPHAMIDE; CYTOKINE; IMMUNOMODULATING AGENT; INTERLEUKIN 6; NITROGEN OXIDE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES TUMOR; BLOOD VESSEL PERMEABILITY; CANDIDA; COMPLEMENT ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMATOPOIESIS; HUMAN; IMMUNOMODULATION; IMMUNOPHARMACOLOGY; IMMUNOTOXICITY; MOUSE; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; SARCOMA 180;

ANIMALS; ANTIBODY FORMATION; ANTIGEN-PRESENTING CELLS; BETA-GLUCANS; CANDIDA; CAPILLARY PERMEABILITY; CELL LINE; CYCLOPHOSPHAMIDE; GLUCANS; INTERLEUKIN-6; LEUKOCYTE COUNT; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED ICR; SARCOMA 180; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034191883     PISSN: 01920561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0192-0561(99)00093-4     Document Type: Article

References (37)

1. Adachi Y., Okazaki M., Ohno, Yadomae T. Enhancement of cytokine production by macrophages stimulated with (1→3)-β-D-glucan, Grifolan (GRN), isolated from Grifola frondosa. Biol. Pharm. Bull. 17:1994;1554-1560.
2. Arika T., Suzuki M., Momoki Y., Saito G. Studies on antitumor activity of schizophyllan (SPG)-4. Jpn J. Clin. Exp. Med. 57:1980;1710-1715.
3. Di Luzio N.R. Update on the immunomodulating activities of glucans. Springer Semin. Immunopathol. 8:1999;387-400.
4. Fujimoto S., Orita K., Kondoh T., Taguchi T., Yoshida K., Kimura T., et al. Schizophyllan. Biotherapy. 2:1988;500-508.
5. Hashimoto T., Ohno N., Adachi Y., Yadomae T. Subgrouping immunomodulating β-glucans by monitoring IFN-γ and NO syntheses. Drug Development Research. 42:1997;35-40.
6. Hashimoto T., Ohno N., Adachi Y., Yadomae T. Nitric oxide synthesis in murine peritoneal macrophages by fungal β-glucans. Biol. Pharm. Bull. 20:1997;1006-1009.
7. Iino K., Ohno N., Suzuki I., Sato K., Oikawa S., Yadomae T. Structure function relationship of antitumor β-1, 3-glucan obtained from matted mycelium of cultured Grifola frondosa. Chem. Pharm. Bull. 33:1985;4950-4956.
8. Van Snick J. Interleukin-6: an overview. Annu. Rev. Immunol. 8:1990;253-278.
9. Kondo Y., Kato A., Hojo A., Nozoe S., Takeuchi M., Ochi K. Cytokine-related immunopotentiating activities of paramylon. J. Pharmacobio-Dyn. 15:1992;617-621.
10. Liang J., Melican D., Calro L., Palace G., Fisette L., Armstrong R., Patchen M.L. Enhanced clearance of a multiple antibiotic resistant Staphylococcus aureus in rats treated with PGG-glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity. Int. J. Immunopharmacol. 20:1998;595-614.
11. Mizuki M., Akira T., Amemiya, Fujiwara M. Cooperative role of T lymphocytes and macrophages in antitumor activity of mice pretreated with schizophyllan (SPG). Jpn J. Exp. Med. 52:1982;59-65.
12. Mohagheghpour N., Dawson M., Hobbs P., Judd A., Winant R., Dousman I., et al. Glucans as immunological adjuvants. Adv. Exp. Med. Biol. 383:1995;13-22.
13. Momoki Y., Arika T., Saito G. Studies on antitumor activity of schizophyllan (SPG)-1. Jpn J. Clin. Exp. Med. 55:1978;3736-3740.
14. Momoki Y., Arika T., Saito G. Studies on antitumor activity of schizophyllan (SPG)-2. Jpn J. Clin. Exp. Med. 56:1979;2039-2045.
15. Muller A., Ensley H., Pretus H., McNamee R., Jones E., McLaughlin E., et al. The application of various protic acids in the extraction of (1→3)-beta-D-glucan from Saccharomyces cerevisiae. Carbohydr. Res. 299:1997;203-208.
16. Ohno N., Yadomae T. Two different conformations of the antitumour β-D-glucan produced by Sclerotinia sclerotiorum IFO 9395. Carbohydr. Res. 159:1987;293-302.
17. Ohno N., Uchiyama M., Tsuzuki A., Tokunaka K., Miura N.N., Adachi Y., et al. Solubilization of yeast cell wall (1→3)-β-D-glucan by sodium hypochlorite oxidation and dimethylsulfoxide extraction. Carbohydr. Res. 316:1999;161-172.
18. Ohno N., Asada N., Adachi Y., Yadomae T. Enhancement of LPS triggered TNF-α (Tumor Necrosis Factor-α) production by (1→3)-β-D-glucans in mice. Biol. Pharm. Bull. 18:(1):1995;126-133.
19. Ohno N., Iino K., Takeyama T., Suzuki I., Sato K., Oikawa S., et al. Structural characterization and antitumor activity of the extracts from matted mycelium of cultured Grifola frondosa. Chem. Pharm. Bull. 33:1985;3395-3401.
20. Ohno N., Adachi Y., Suzuki I., Oikawa S., Sato K., Ohsawa M., Yadomae T. Antitumor activity of a β-1, 3-glucan obtained from liquid cultured mycelium of Grifola frondosa. J. Pharmacobio-Dyn. 9:1986;861-864.
21. Rios-Hernandez M., Dos-santos N.J., Silvia-Cardosa, Bello-Garciga J.L., Pedroso M. Immunopharmacological studies of beta-1,3-glucan. Arch. Med. Res. 25:1994;179-180.
22. Sasaki T., Abiko N., Sugino Y., Nitta K. Dependence on chain length of antitumor activity of (1→3)-β-D-glucan from Alcaligenes faecalis var. myxogenes, IFO13140, and its acid degraded products. Cancer Res. 38:1978;379-383.
23. Sasaki T., Takasuka N., Chihara G., Maeda Y. Antitumor activity of degraded products of lentinan: Its correlation with molecular weight. Gann. 67:1976;191-195.
24. Shiio T., Yoshihama T., Yugari Y. Effect of antitumor polysaccharide lentinanon immune response and its additive effect other chemotherapeutic agents. Jpn J. Cancer Chemother. 2:1975;45-51.
25. Soltys J., Quinn M.T. Modulation of endotoxin- and enterotoxin-induced cytokine release by in vivo treatment with β-(1,6)-branched β-(1,3)-glucan. Infect. Immun. 67:1999;244-252.
26. Sugawara I., Lee K.C., Wong M. Schizophyllan (SPG)-treated macrophages and antitumor activities against syngeneic and allogeneic tumor cells I. Characteristics of SPG-treated macrophages. Cancer Immunol. Immunother. 16:1984;137-144.
27. Suzuki T., Ohno N., Saito K., Yadomae T. Activation of the complement system by (1→3)-β-D-glucans having different degrees of branching and different ultrastructures. J. Pharmacobio-Dyn. 15:1992;277-285.
28. Taguchi T., Kaneko Y., Chihara G. Lentinan. Biotherapy. 2:1988;509-521.
29. Tateishi T., Ohno N., Adachi Y., Yadomae T. Iincreases in hematopoietic responses caused by β-glucans in mice. Biosci. Biotech. Biochem. 61:1997;1548-1553.
30. Thornton B.P., Vetvicka V., Pitman M., Goldman R.C., Ross G.D. Analysis of the sugar specificity and molecular location of the beta glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J. Immunol. 156:1996;1235-1246.
31. Tsuzuki A., Tateishi T., Ohno N., Adachi Y., Yadomae T. Increase of hematopoietic response by triple or single helical conformer of an antitumor (1→3)-β-glucan preparation, sonifilan, in cyclophosphamide-induced leukopenic mice. Biosci. Biotechnol. Biochem. 63:1999;104-110.
32. Watanabe N., Niitsu Y. Antitumor effect of tumor necrosis factor. Biotherapy. 5:1991;1634-1643.
33. Williams D.L., Pretus H.A., McNamee R.B., Jones E.L., Ensley H.E., Browder I.L. Development of a water-soluble, sulfated (1→3)-beta-D-glucan biological response modifier derived from Saccharomyces cerevisiae. Carbohydr. Res. 235:1992;247-257.
34. Xia Y., Vetvicka V., Yan Jun, Hanikyrova M., Mayadas T., Ross G.D. The β-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J. Immunol. 162:1999;2281-2290.
35. Yadomae T., Ohno N. Structure-activity relationship of immunomodulating (1→3)-β-D-glucan. Recent Res. Devel. in Chem. & Pharm. Sciences. 1:1996;23-33.
36. Yadomae T. Immunopharmacological activity of β-glucan: structure-activity relationship in relation to various conformations. Jpn J. Med. Mycol. 33:1992;267-277.
37. Zakany J., Chihara G., Fachet J. Effect of lentinan on tumor growth in murine allogeneic and syngeneic hosts. Int. J. Cancer. 25:1980;371-376.